Abstract
The intravenous infusion of desmopressin acetate (DDAVP), a synthetic vasopressin analogue, has been shown to cause a sustained increase in all Factor VIII related properties (VIII-C, VIIIR-Ag, VIIIR-WF) in patients with mild to moderate hemophilia and von Willebrand's disease. This study examines the effect of high doses of intranasal DDAVP (0.4 μg/kg BiD) in four patients with hemophilia A and one patient with von Willebrand's disease. In spite of a physiologic response with a decrease in urine volume and increase in urine osmolality, there was no effect on the Factor VIII complex.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
